TBIO
2024-09-30 | ||||
---|---|---|---|---|
Revenue from contract with customer, excluding assessed tax | 1,566 | |||
Cost of revenue, total | 557 | |||
Gross profit | 1,009 | |||
Selling and marketing expense, total | 880 | |||
Research and development expense, total | 2,174 | |||
General and administrative expense, total | 3,099 | |||
Impairment charges | 333 | |||
Operating expenses | 6,486 | |||
Operating income (loss) | -5,477 | |||
Other (expense) income, net | -72 | |||
Interest expense, includes related-party amounts of 169 for the three and nine months ended september 30, 2024 and 0 for the three and nine months ended september 30, 2023, respectively | 219 | |||
Interest and other income | 78 | |||
Loss on extinguishment of notes payable | -491 | |||
Nonoperating income (expense) | -704 | |||
Income (loss) from continuing operations before income taxes, noncontrolling interest | -6,181 | |||
Income tax expense (benefit), total | 1 | |||
Income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest | -6,182 | |||
Net loss from discontinued operations | -460 | |||
Net loss | -6,642 | |||
Less redeemable convertible preferred stock dividends | 615 | |||
Net income (loss) available to common stockholders, basic | -7,257 | |||
Basic eps | -4.09 | |||
Diluted eps | -4.09 | |||
Basic average shares | 1,772,663 | |||
Diluted average shares | 1,772,663 |